Compare Oracle Corporation (ORCL) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Oracle Corporation vs Zimmer Biomet Holdings Inc — how do they compare? Oracle Corporation trades at $125.9 (market cap $365.96B), while Zimmer Biomet Holdings Inc trades at $88.69 (market cap $17.20B). The key difference: Oracle Corporation is far larger — about 21.3× Zimmer Biomet Holdings Inc's market cap, and Oracle Corporation pays the higher dividend (1.57%). Which is the better fit depends on your goals.
| ORCL | ZBH | |
|---|---|---|
Market Cap | $365.96B | $17.20B |
Sector | Technology | Health |
52-Week High | $328.33 | $107.71 |
52-Week Low | $121.37 | $79.58 |
Enterprise Value | $495.21B | $24.25B |
Dividend Yield | 1.57% | 1.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Oracle Corporation (ORCL) trades at $125.86, up 3.7% with strong recent earnings beats. The stock shows bearish technical signals but maintains robust fundamentals with 21.67% net margins and consistent revenue growth. Recent AI partnerships and infrastructure investments position Oracle as a key player in the enterprise cloud and AI markets, though high valuation multiples and significant debt levels warrant caution.
Oracle presents a compelling growth story driven by AI infrastructure demand, with analyst consensus strongly bullish (65% buy ratings) and a $253.30 price target representing significant upside. Key risks include high leverage, competitive pressures, and execution challenges in capital-intensive AI expansion. The upcoming Q2 2026 earnings report on June 10 will be critical for validating the AI growth narrative.
Zimmer Biomet (ZBH) trades at $88.92, down 2.41% on the day, with a bearish technical signal but strong fundamentals including a 70.03% gross margin and three consecutive quarterly EPS beats. Revenue grew to $8.23B in 2025, though net income margin compressed to 8.56%. The company announced a $1 billion share repurchase increase and expansion in India, while maintaining a dividend.
The stock offers a 10% upside to the $97.67 consensus price target, supported by value metrics and operational strength, but faces risks from rising debt levels and competitive pressures. Analyst sentiment is mixed with 40% buy ratings, suggesting cautious optimism amid near-term technical weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Oracle Corporation
Oracle provides database technology and enterprise resource planning, or ERP, software to enterprises around the world. Founded in 1977, Oracle pioneered the first commercial SQL-based relational database management system. Today, Oracle has 430,000 customers in 175 countries, supported by its base of 136,000 employees.
Read more on ORCL →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
